Nippon Shinyaku's leukemia treatment approved for Japanese market.
In: PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 20-20
report
Zugriff:
Reports that Nippon Shinyaku Co. Ltd. has received approval from the Japanese Ministry of Health and Welfare to market Trisenox for patients with relapsed or refractory acute promyelocytic leukemia (APL) in Japan. Entry of Nippon into a marketing and distribution agreement with CTI Technologies Inc.; Terms of the agreement; Clinical characteristics of APL.
Titel: |
Nippon Shinyaku's leukemia treatment approved for Japanese market.
|
---|---|
Zeitschrift: | PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 20-20 |
Veröffentlichung: | 2004 |
Medientyp: | report |
Schlagwort: |
|
Sonstiges: |
|